Overview

Trilostane for Androgen-Independent Prostate Cancer

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to test the safety of trilostane by looking at what effects, good and bad, it has on patients with androgen-independent prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Androgens
Cortisol succinate
Dihydrotestosterone
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Trilostane